Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (323)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02311920 | Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | completed | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05671016 | Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy(BRITER) | completed | — | 125 | Brighton and Sussex University Hospitals NHS TrustOTHER | 1 |
| Jan 4, 2023 |
| clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04444427 | Evaluation of GLR2007 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 19 | Gan and Lee Pharmaceuticals, USAINDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT01301430 | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.(ParvOryx01) | completed | Phase 1 / Phase 2 | 18 | Oryx GmbH & Co. KGINDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01865162 | Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study(KGDinGBM) | completed | Phase 1 | 6 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03291977 | Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)(FLEGME) | completed | Phase 3 | 51 | Rennes University HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT02858895 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 47 | Medicenna Therapeutics, Inc.INDUSTRY | 1 | Oct 24, 2022 | clinicaltrials |
| NCT02336165 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | completed | Phase 2 | 159 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 12, 2022 | clinicaltrials |
| NCT00687765 | Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 / Phase 2 | 126 | SanofiINDUSTRY | 1 | Sep 14, 2022 | clinicaltrials |
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | completed | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02926222 | Regorafenib in Relapsed Glioblastoma(REGOMA) | completed | Phase 2 | 119 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03744026 | Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9(SC9-GBM-01) | completed | Phase 1 / Phase 2 | 38 | CarTheraINDUSTRY | 2 | Sep 7, 2022 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02302235 | Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study(GBMXRT) | completed | Phase 2 | 42 | Mid-Atlantic Epilepsy and Sleep Center, LLCOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04596930 | MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma(EMITT) | completed | N/A | 15 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05476341 | A Phase I Clinical Trial of Bevacizumab Injection | completed | Phase 1 | 98 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 27, 2022 | clinicaltrials |
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03397953 | Vinorelbine for Recurrent ACLC | completed | Phase 2 | 20 | Children's Cancer Group, ChinaNETWORK | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT01808820 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | completed | Phase 1 | 20 | Macarena De La Fuente, MDOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT03367715 | Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma | completed | Phase 2 | 10 | NYU Langone HealthOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02968940 | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | completed | Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT02644291 | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | completed | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02330562 | Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab | completed | Phase 1 / Phase 2 | 121 | CelgeneINDUSTRY | 2 | Jun 8, 2022 | clinicaltrials |
| NCT01664182 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01434602 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02709616 | Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)(PERCELLVAC) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT02808364 | Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)(PerCellVac2) | completed | Phase 1 | 10 | Guangdong 999 Brain HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT02871843 | RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas(G-FORCE-1) | completed | Phase 1 | 19 | EpicentRx, Inc.INDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT03216499 | HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma(PT2385) | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT02794883 | Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma | completed | Phase 2 | 36 | Northwestern UniversityOTHER | 1 | Apr 18, 2022 | clinicaltrials |
| NCT03390569 | Exercise in Patients With Glioblastoma | completed | N/A | 54 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT01004874 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | completed | Phase 2 | 80 | Duke UniversityOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT02750891 | A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas | completed | Phase 1 / Phase 2 | 18 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02843230 | Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI | completed | — | 30 | Massachusetts General HospitalOTHER | 1 | Apr 8, 2022 | clinicaltrials |
| NCT01904123 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | completed | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT00303849 | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | completed | Phase 1 / Phase 2 | 33 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02359097 | Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma | completed | N/A | 29 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04516733 | Precoce Medical Care by the Mobil Support for Patients With Glioblastoma(GLIOSUPPORT) | completed | N/A | 35 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02270034 | Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03341806 | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | completed | Phase 1 | 13 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT01222754 | Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2022 | clinicaltrials |
| NCT03990285 | [18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )(Axumin) | completed | Phase 1 | 30 | Ali NabavizadehOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00805961 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | completed | Phase 2 | 68 | SCRI Development Innovations, LLCOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas(ECHELON-2) | completed | Phase 3 | 452 | Seagen Inc.INDUSTRY | 16 | Nov 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 10, 2023source: clinicaltrials